795551--3/13/2006--THERAGENICS

related topics

{product, market, service}

{cost, operation, labor}

{product, liability, claim}

{acquisition, growth, future}

{cost, regulation, environmental}

{property, intellectual, protect}

{regulation, change, law}

{interest, director, officer}

{regulation, government, change}

{personnel, key, retain}

{stock, price, operating}

{loan, real, estate}

{financial, litigation, operation}

The Company cautions the reader that the risk factors discussed below may not be exhaustive. The Company operates in a continually changing business environment and new risk factors may emerge from time to time. The Company can not predict such new risk factors, nor can it assess the impact, if any, of such new risk factors on the Company s business or the extent to which any factor or combination of factors may cause actual results to differ materially from those expressed in any forward-looking statement. Risks Related to our Business There are risks associated with our acquisitions, potential acquisitions and joint ventures. We may not realize the benefits of the CP Medical acquisition. The cost of the CP Medical acquisition could harm our financial results. We are dependent on key personnel. Our stock price has and may continue to be subject to large fluctuations. We are subject to stringent government regulation. We face risk related to lack of diversification. We are dependent on new technological development. We are highly dependent on our marketing and advertising specialists and our direct sales organization. Any failure to build and manage our direct sales organization could negatively affect our revenues. We depend partially on our relationships with distributors and other industry participants to market TheraSeed and I-Seed and certain of our CP Medical products, and if these relationships are discontinued or if we are unable to develop new relationships, our revenues could decline. Doctors and hospitals may not adopt our products and technologies at levels sufficient to sustain our business or to achieve our desired growth rate. Evolving regulation of corporate governance and public disclosure may result in additional expenses and continuing uncertainty. There are limitations on our ability to protect our intellectual property and we are dependent on trade secrets. We are dependent on Medicare reimbursement policies. We may be unable to maintain sufficient liability insurance. If we do not comply with laws and regulations relating to our use of hazardous materials, we may incur substantial liabilities. Litigation may harm our business or otherwise distract our management. Defects in, or misuse of, our products, or any detrimental side effects that result from the use of our products, could result in serious injury or death and could require costly recalls or subject us to costly and time-consuming product liability claims. This could harm future sales and require us to pay substantial damages. We may require additional capital in the future and we may be unable to obtain capital on favorable terms or at all. If we are unable to develop new enhancements and new generations of brachytherapy products and innovative sutures, we may be unable to retain our existing customers or attract new customers. We may not be successful in implementing our restructuring initiatives. Our restructuring of operations may not achieve the results we intend and may harm our business.

Full 10-K form ▸

795551--3/13/2006--THERAGENICS_CORP